11th COVID-19 Vaccine Approved by the WHO

The World Health Organization (WHO) announced today it issued an emergency use listing (EUL) for CONVIDECIA, a modified human adenovirus COVID-19 vaccine manufactured by CanSino Biologics.

The eleven COVID-19 vaccines Listed by the WHO are published on this webpage.

CONVIDECIA was assessed under the WHO EUL procedure based on the quality, safety, efficacy, a risk management plan, programmatic suitability, and a manufacturing site inspection conducted by WHO.

CONVIDECIA was recently found to have 64% efficacy against symptomatic disease and 92% against severe COVID-19 in adults.

And the Technical Advisory Group for Emergency Use Listing, convened by WHO and made up of regulatory experts worldwide, has determined that the vaccine meets WHO standards for protection against COVID-19 and that the vaccine's benefits far outweigh the risks.

Additionally, CONVIDECIA was reviewed earlier in May 2022 by WHO's Strategic Advisory Group of Experts on Immunization, which formulates vaccine-specific policies and recommendations for vaccines' use in populations.

The WHO EUL procedure assesses the suitability of novel health products during public health emergencies.

Note: The WHO press release issued on May 19, 2022, was manually curated for mobile readership.